Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Condition: Well-differentiated Non-pancreatic Neuroendocrine CarcinomaInterventions: Drug: Axitinib; Drug: Sandostatin LAR; Drug: PlaceboSponsor: Grupo Espanol de Tumores NeuroendocrinosActive, not recruiting - verified December 2014

http://clinicaltrials.gov/ct2/show/NCT01744249?lup_s=11%2F30%2F2014&lup_d=30

Source: ClinicalTrials.gov - September 25, 2012 Category: Research Source Type: clinical trials